Interested in receiving FDA-TRACK updates in your inbox?
On August 14, 2018, the second reauthorization of the Animal Generic Drug User Fee Act (AGDUFA), referred to as AGDUFA III, was signed into law. ADUFA III amends the Federal Food, Drug, and Cosmetic Act (FD&C Act) by reauthorizing AGDUFA for an additional five years (FY 2019 through FY 2023). AGDUFA provides FDA with resources to enhance the performance and predictability of the generic new animal drug review process resulting in more readily available safe and effective new products.
The Animal Generic Drug User Fee Performance Dashboards (AGDUFA Dashboards) provide a concise, interactive, and visual presentation of data presented in the legislatively mandated FY 2021 AGDUFA Performance Report to Congress for the Animal Generic Drug User Fee Act (the Report). The AGDUFA Dashboards are not intended to replace the Report and are to be used as a supplemental tool for viewing the data. The AGDUFA Dashboards reflect performance on submissions received and actions taken as of September 30, 2021. The AGDUFA Dashboards present final performance in meeting AGDUFA goals for FY 2020 and preliminary performance for FY 2021. Final AGDUFA performance data for FY 2021 will be presented in the FY 2022 AGDUFA Report and referenced in updated versions of the AGDUFA Dashboards.
The Animal Generic Drug Applications and Supplements Dashboard displays current performance relating to the review of:
- Original Abbreviated New Animal Drug Applications (ANADAs) and Reactivations
- Administrative ANADAs
- Manufacturing Supplemental ANADAs and Reactivations
- Generic Investigational New Animal Drug (JINAD) Study Submissions
- JINAD Protocol Submissions
For historical performance goals, please see the Historical Performance: Animal Generic Drug Applications and Supplements Dashboard.